News Release
Biosimilar Drugs Could Generate $38.4 Billion in Savings over Five Years
Jan 10, 2022
Projected US Savings From Biosimilars, 2021–2025
Published in: American Journal of Managed Care, Volume 28, No. 7 (July 2022)
Posted on RAND.org on January 26, 2022
Read More
Access further information on this document at www.ajmc.comThis article was published outside of RAND. The full text of the article can be found at the link above.
Substituting biosimilar drugs for biologics could drive down the price of expensive medicines used to treat illnesses such as cancer and rheumatoid arthritis, with savings estimated to be $38.4 billion or 5.9% of projected total U.S. spending on biologics from 2021 to 2025.
Access further information on this document at www.ajmc.com
This article was published outside of RAND. The full text of the article can be found at the link above.
Related Products
Research conducted by
This report is part of the RAND Corporation External publication series. Many RAND studies are published in peer-reviewed scholarly journals, as chapters in commercial books, or as documents published by other organizations.
Our mission to help improve policy and decisionmaking through research and analysis is enabled through our core values of quality and objectivity and our unwavering commitment to the highest level of integrity and ethical behavior. To help ensure our research and analysis are rigorous, objective, and nonpartisan, we subject our research publications to a robust and exacting quality-assurance process; avoid both the appearance and reality of financial and other conflicts of interest through staff training, project screening, and a policy of mandatory disclosure; and pursue transparency in our research engagements through our commitment to the open publication of our research findings and recommendations, disclosure of the source of funding of published research, and policies to ensure intellectual independence. For more information, visit www.rand.org/about/research-integrity.
The RAND Corporation is a nonprofit institution that helps improve policy and decisionmaking through research and analysis. RAND's publications do not necessarily reflect the opinions of its research clients and sponsors.